Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
暂无分享,去创建一个
D. Blanset | B. Gorovits | P. Andrews | S. Thibault | S. Roberts | Pauline L. Martin | K. Flagella | C. Lynch | K. Kramer-Stickland | G. Warner | Kelly M. Flagella